Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Cardinal Health (CAH) to $220 from $190 and keeps an Outperform rating on the shares. Cardinal Health kicked off FY26 with a “bang,” showcasing robust performance across all segments and a notable 37% year-over-year adjusted operating income increase as Pharma execution shines, “Other” accelerates, and Global Medical Products and Distribution margins recover, the analyst tells investors in a research note. The firm added that the outlook suggests even more potential upside.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $220 from $185 at UBS
- Cardinal Health price target raised to $232 from $208 at Baird
- Cardinal Health price target raised to $190 from $165 at Citi
- Cardinal Health Reports Strong Revenue Growth in Latest Quarter
- Cardinal Health price target raised to $216 from $180 at BofA